News

Media

Conferences

Publications

Clinical

Events

Resources

Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 12

Opinion

Video

May 28, 2024

Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Heather Moore, BCOP, CPP, PharmD

Frank Scimeca, PharmD, MBA, BCOP, discusses strategies for implementing cost-saving measures and utilizing patient assistance programs to help patients access therapy, while emphasizing the importance of mitigating financial toxicities for patients.

EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer

EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer

EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer

EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer

EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients

EP: 7.Highlighting the Available CDK4/6 Inhibitors

EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC

EP: 9.Applying NCCN Guidelines in the Treatment of mBC

EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events

Now Viewing

Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs

EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer

EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer

EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer

EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer

EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients

EP: 7.Highlighting the Available CDK4/6 Inhibitors

EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC

EP: 9.Applying NCCN Guidelines in the Treatment of mBC

EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events

EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs

EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 14.Academic and Community Practice Collaboration in mBC Treatment

EP: 15.Defining the Standard of Care for Early Breast Cancer Treatment

EP: 16.Balancing Clinical and Economic Factors in Early Breast Cancer Treatment

EP: 17.Alternative Treatments for eBC and mBC

EP: 18.Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective

EP: 19.Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care

EP: 20.Key Takeaways on mBC and eBC